Shares of Organon & Co. have moved -5.6% today, and are now trading at a price of $19.83. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 3,164,356 compared to the stock's average volume of 1,994,391.
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Based in Jersey City, United States the company has 10,000 full time employees and a market cap of $5,067,913,216. Organon & Co. currently offers its equity investors a dividend that yields 5.3% per year.
The company is now trading -36.03% away from its average analyst target price of $31.0 per share. The 6 analysts following the stock have set target prices ranging from $23.0 to $43.0, and on average give Organon & Co. a rating of hold.
Over the last 12 months OGN shares have declined by -30.0%, which represents a difference of -44.0% when compared to the S&P 500. The stock's 52 week high is $32.43 per share and its 52 week low is $18.87. With its net margins declining an average -15.9% over the last 2 years, Organon & Co. declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-27 | 6,174,000 | 917,000 | 15 | -28.57 |
| 2022-03-21 | 6,304,000 | 1,351,000 | 21 |
